DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA ( R / R LBCL)

Journal article

Peer reviewed

F. L. Locke, L. Lekakis, H. Eradat, J. Munoz, M. Tees, S. de Vos, R. Nath, D. Stevens, S. Malik, L. Popplewell, …

Hematological oncology, Vol.41(S2), pp.85-86

2023-06

Metrics

1 Record Views

Title: DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA ( R / R LBCL)
Creators: F. L. Locke - Moffitt Cancer Center
L. Lekakis - University of Miami
H. Eradat - Ronald Reagan UCLA Medical Center
J. Munoz - Mayo Clinic in Florida
M. Tees - Colorado Blood Cancer Institute
S. de Vos - UCLA Health
R. Nath - Banner Health
D. Stevens - Norton Healthcare
S. Malik - St David's Medical Center
L. Popplewell - City Of Hope National Medical Center
M. Hamadani - Medical College of Wisconsin
O. Oluwole - Vanderbilt University Medical Center
M. Perales - Memorial Sloan Kettering Cancer Center
D. Miklos - Stanford University
P. Fisher - Allogene Therapeutics
L. Goyal - Allogene Therapeutics
L. Navale - Allogene Therapeutics
G. Kaufman - Allogene Therapeutics
K. Kai - Allogene Therapeutics
A. Balakumaran - Allogene Therapeutics
S. Neelapu - The University of Texas MD Anderson Cancer Center
Publication Details: Hematological oncology, Vol.41(S2), pp.85-86
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031821346302976